Drugs / SB17
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04967508 | Jul 2021 → Feb 2022 | psoriasis | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-09-11 | Novartis Pharmaceuticals | Sandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offering novartis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB17 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04967508 ↗ |
| Known as | Ustekinumab | “SB17 (Proposed Ustekinumab Biosimilar)” NCT04967508 ↗ |
| Route | Subcutaneous | “via subcutaneous injection” NCT04967508 ↗ |